Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1PI9G)

Drug Name

NN8717 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Graft-versus-host disease	4B24	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor XIII (F13B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN1841	DMDGK83	Hemophilia	3B10.0	Phase 3	[3]
Tridegin	DMUHBSI	Thrombosis	DB61-GB90	Terminated	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of Novo Nordisk A/S.
2	Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14.
3	Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13.
4	Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997 Jun 15;324 ( Pt 3):797-805.